respiratory
Lung cancer

Novel therapies begin to ‘outsmart’ ALK-positive NSCLC


Rare ALK+ non-small cell lung cancer (NSCLC) can achieve an ‘impressive’ overall survival of almost four years (46 months) when aggressively managed, Australian clinicians have shown. A study of 35 patients identified between 2010 and 2016 at the Royal North...

Rare ALK+ non-small cell lung cancer (NSCLC) can achieve an ‘impressive’ overall survival of almost four years (46 months) when...

Read more